Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PAVmed Inc.
  6. Summary
    PAVM   US70387R1068

PAVMED INC.

(PAVM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
4.26(c) 3.81(c) 3.84(c) 4.01(c) 3.81(c) Last
2 121 869 2 787 223 3 156 158 2 293 900 1 121 198 Volume
+2.40% -10.56% +0.79% +4.43% -4.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,53 M - -
Net income 2021 -47,4 M - -
Net cash position 2021 49,0 M - -
P/E ratio 2021 -6,51x
Yield 2021 -
Sales 2022 8,13 M - -
Net income 2022 -44,5 M - -
Net cash position 2022 49,0 M - -
P/E ratio 2022 -7,43x
Yield 2022 -
Capitalization 335 M 335 M -
EV / Sales 2021 545x
EV / Sales 2022 35,2x
Nbr of Employees 25
Free-Float 89,5%
More Financials
Company
PAVmed Inc. is a multi-product, commercial-stage technology medical device company. The Company has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related... 
More about the company
Ratings of PAVmed Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about PAVMED INC.
11/22PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/22PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
11/17Health Care Stocks Manage Modest Gains Wednesday
MT
11/17Health Care Stocks Moderately Higher This Afternoon
MT
11/17PAVmed Shares Drop After Reporting Wider Q3 Adjusted Loss
MT
11/17Wall Street Set to Open Largely Flat, Stabilizing After Boost From Data, Retail Earning..
MT
11/17Health Care Stocks Flat To Lower Premarket Wednesday
MT
11/17Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digi..
BU
11/17Top Premarket Decliners
MT
11/17PAVmed's Q3 Adjusted Loss Widens
MT
11/11PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
BU
11/04PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021 - F..
PU
10/29Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
BU
10/28Lucid Diagnostics' EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of t..
BU
10/25PAVMED : Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Of..
PU
More news
News in other languages on PAVMED INC.
11/17Les actions du secteur de la santé affichent des gains modestes mercredi
11/17Les actions du secteur de la santé en hausse modérée cet après-midi
11/17Les actions de PAVmed chutent après l'annonce d'une perte ajustée plus importante au tr..
11/17Les actions du secteur de la santé sont plates ou en baisse mercredi avant le marché
11/17La perte ajustée de PAVmed au troisième trimestre s'accentue
More news
Analyst Recommendations on PAVMED INC.
More recommendations
Chart PAVMED INC.
Duration : Period :
PAVmed Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PAVMED INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,81 $
Average target price 10,00 $
Spread / Average Target 162%
EPS Revisions
Managers and Directors
Lishan Aklog Chairman & Chief Executive Officer
Dennis M. McGrath President, Chief Financial Officer & Secretary
Brian J. deGuzman Chief Medical Officer
Michael J. Glennon Vice Chairman
Ronald M. Sparks Independent Director
Sector and Competitors